Teva Announces Donations of Essential Medicines in Support of Ukrainian Refugees

  • Teva is donating medicines valued at over $11M, for acute therapies in support of Ukrainian refugees

  • The donations include over 1 million packages of antibiotics and other essential medicines as well as hygienic products for Ukrainian infants and children

TEL AVIV, ISRAEL— 14 March, 2022– Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced a donation of essential medical products valued at over $11M, for acute therapies in humanitarian support of Ukrainian refugees.

The donations made by Teva include over 1.3 million packs of medicines, valued at over $10.8 million (wholesale acquisition cost), most of which have been made in partnership with Teva's trusted long-term partner 'Direct Relief'. Many of the Teva medicines donated are listed on the World Health Organization’s list of essential medicines, and include antibiotics, treatment for respiratory conditions, and other treatments.

Teva has also donated over 25,000 packs of antibiotics valued at approximately $180,000 to 'United Hatzalah', a leading Israeli non-profit emergency and relief organization, as aid in refugee camps and field hospitals on the border of Ukraine. The medicines arrived at the border of Ukraine last week and are helping to treat thousands of refugees who have fled the war.

Moreover, Teva is cooperating with 'People in Need', a European NGO, to provide around 82,000 packs of medicines valued at approximately $180,000 for Ukrainian infants and children that are struggling with poor hygienic conditions as a result of the humanitarian crisis.

As a leading pharmaceutical company we are upholding our responsibility and commitment to provide critical and essential medicine to all patients, wherever they are in the world. In accordance with Teva's mission to provide access to quality medicines and improving the lives of patients across the world we are currently assessing additional donations programs throughout Europe, and are maintaining dialogue with our network of trusted partners and other international humanitarian aid organizations to understand the emerging needs, and make a contribution through our expertise and supply chain, while doing everything possible to also continue to supply our vast portfolio of essential medicines to other patients.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products.
Learn more at